SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chip

Chip is actively trending as investors debate its role as a specialized infrastructure financing layer for AI hardware versus claims that it acts as a high-risk pump-and-dump scheme. While some in the community highlight its real-world utility in GPU-backed lending and institutional partnerships, skeptics point to significant supply overhang and persistent downward price pressure as reasons to remain cautious.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing intense community debate as traders weigh the potential for a Russell 2000 inclusion-driven breakout against concerns over recent volatility and lingering litigation. Investors are closely tracking the company's critical role in the aerospace and defense sectors, while many are actively discussing whether to accumulate shares ahead of potential commercial catalysts or prepare for further technical consolidation.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure and negative sentiment, with community members expressing deep frustration over the token's persistent underperformance compared to the broader crypto market. Investors are actively debating whether these multi-year lows represent a final capitulation point and a rare accumulation opportunity for its real-world technology, or if the project is entering a terminal decline due to concerns over tokenomics and lack of bullish momentum.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty Industries is trending as investors react to the company's ramp-up in tungsten production at its Sangdong mine, viewed as a critical supply chain asset for Western defense and semiconductor industries. The community is actively discussing the potential for a share price re-rating driven by strong institutional accumulation, bullish analyst coverage, and the company's strategic position ahead of future critical mineral supply mandates.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF (KWEB) is attracting heavy institutional call volume as investors rotate into Chinese tech, betting on a potential rebound driven by AI innovation and undervalued sector multiples. Community sentiment remains polarized between those viewing current prices as a deep value opportunity and skeptics who remain wary of regulatory risks and past performance struggles.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing active discussion as investors debate its critical role in connecting traditional finance with blockchain infrastructure, often referencing potential institutional integration and regulatory developments like the Clarity Act. Community sentiment remains polarized, with many traders closely monitoring technical resistance levels while some long-term holders emphasize its utility as an oracle network amid broader market volatility.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is seeing extreme volatility as traders react to a beat-and-raise quarterly report, with the stock oscillating wildly between deep losses and massive gains. The community is actively debating the sustainability of this price action, with many discussing it as a high-stakes battle between algorithmic traders and investors trying to value the stock's role in the evolving enterprise AI data infrastructure.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenus is experiencing significant market interest and high volatility following a private placement designed to fund the pivotal Phase 3 ROBBIN trial for its BOT+BAL combination therapy. The community is actively debating the impact of the financing structure, the strategic pivot toward neoadjuvant colon cancer treatment, and the influence of new institutional directors on long-term corporate governance.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is facing intense community debate as investors remain divided between long-term bullish sentiment over institutional adoption and frustration over persistent price stagnation near the $1 mark. Market participants are actively discussing the impact of potential regulatory shifts and the influence of whale accumulation, while bears continue to highlight concerns regarding token dilution and failed price targets.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block is trending as investors digest news of hedge fund activity and weigh the company's long-term fintech potential against sector-wide consolidation pressure. Community discussion remains polarized, with many focusing on the stock's persistent range-bound trading while others look for potential upside from institutional interest and operational efficiency improvements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alterity Therapeutics Secures Key US Patent for Lead Asset

Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.read more...

Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in premarket trading.read more...

Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study

(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...

Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

Equity

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd - ADR

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$4.79
Prev Close	$4.70
Open	$4.71
Dividend Yield	0.00%
50-Day Moving Average	$4.77
Beta	0.88
Avg. Volume	14,185.46
PE Ratio	-0.26

52-Week High	$5.89
52-Week Low	$2.66
Market Capitalization	$87.01M
EPS (Annual)	-$0.7383
Price to Book	0.05
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info